Key result
Genome-wide association studies, polygenic risk scores, and AI/ML using big data facilitate personalized treatment strategies for patients with cardiovascular disease.
This paper discusses the potential of genome-wide association studies, polygenic risk scores, and artificial intelligence/machine learning in enabling personalized treatment for cardiovascular disease.
Hypothesis-generating for personalized CVD strategies; prospective validation required before clinical adoption.
Tweetable abstract Role of GWAS, polygenic risk score and AI/ML using big data for personalized treatment to the patients with cardiovascular disease
No takes yet. Share an insight, caveat, or question.
Abdelhalim et al. (2023) studied this question. Genome-wide association studies, polygenic risk scores, and AI/ML using big data facilitate personalized treatment strategies for patients with cardiovascular disease.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: